Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) Short Interest Update

Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) was the target of a large growth in short interest during the month of March. As of March 15th, there was short interest totalling 53,600 shares, a growth of 26.7% from the February 28th total of 42,300 shares. Based on an average daily volume of 66,000 shares, the short-interest ratio is currently 0.8 days. Currently, 2.9% of the shares of the stock are short sold.

Lixte Biotechnology Price Performance

Shares of LIXT stock traded up $0.03 during trading hours on Wednesday, hitting $1.22. The stock had a trading volume of 17,001 shares, compared to its average volume of 188,215. The stock has a market capitalization of $3.27 million, a price-to-earnings ratio of -0.71 and a beta of 0.19. The stock’s 50-day moving average price is $1.62 and its two-hundred day moving average price is $1.85. Lixte Biotechnology has a one year low of $1.02 and a one year high of $3.80.

Lixte Biotechnology (NASDAQ:LIXT) last posted its earnings results on Monday, March 24th. The company reported ($0.27) EPS for the quarter.

Hedge Funds Weigh In On Lixte Biotechnology

An institutional investor recently bought a new position in Lixte Biotechnology stock. TIAA Trust National Association purchased a new position in Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 101,834 shares of the company’s stock, valued at approximately $207,000. TIAA Trust National Association owned approximately 4.53% of Lixte Biotechnology at the end of the most recent quarter. 5.10% of the stock is currently owned by institutional investors.

Lixte Biotechnology Company Profile

LIXTE Biotechnology Holdings, Inc, a clinical-stage pharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colon cancer.